Clinical Trial Update: AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 trial of AGN-229666 ophthalmic solution for seasonal or perennial allergic conjunctivitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Conjunctivitis
• Seasonal Allergic Conjunctivitis

Drugs mentioned

• AGN-229666 ophthalmic solution

Snippet

Sponsor: Allergan | Conditions: Conjunctivitis, Allergic | Phase 3 | Status: COMPLETED | Results posted: 2015-10-08